The challenge of diagnosing and classifying eosinophilia and eosinophil disorders: A review.

IF 1.5 4区 医学 Q4 IMMUNOLOGY Central European Journal of Immunology Pub Date : 2024-01-01 Epub Date: 2024-04-19 DOI:10.5114/ceji.2024.136512
Agnieszka Szymczyk, Jakub Jaworski, Monika Podhorecka
{"title":"The challenge of diagnosing and classifying eosinophilia and eosinophil disorders: A review.","authors":"Agnieszka Szymczyk, Jakub Jaworski, Monika Podhorecka","doi":"10.5114/ceji.2024.136512","DOIUrl":null,"url":null,"abstract":"<p><p>Eosinophilia is a feature of multiple conditions, both hematologic and non-hematologic, and may be associated with organ damage. The pathogenesis of eosinophilia can follow two distinct pathways. Primary eosinophilia is caused by a cell-intrinsic mechanism originating from clonal expansion of eosinophils through acquisition of a somatic mutation, such as FIP1L1-PDGFRA. In recent years, great progress has been made in the field of pathogenesis and molecularly targeted therapy of neoplastic eosinophilia. The diagnostic procedure should include, among other things, morphologic analysis of blood and bone marrow samples, cytogenetics and fluorescence in situ-hybridization tests to detect evidence of an acute or chronic myeloid or lymphoid disorder. Secondary eosinophilia follows a cell-extrinsic mechanism as a response to exogenous cytokines. In most clinical cases, peripheral blood eosinophilia is reactive and typically associated with non-hematological disorders such as infections, allergic conditions, connective tissue disorders, vasculitis, malignancy, or endocrinopathies. Nonetheless, the cause of most cases of hypereosinophilic syndrome remains unknown. In this article, we present a short review focused on differential diagnosis of eosinophilia and eosinophilic disorders. The diagnosis of eosinophilia is a challenge for physicians; thus this review may be useful in clinical practice.</p>","PeriodicalId":9694,"journal":{"name":"Central European Journal of Immunology","volume":"49 1","pages":"60-69"},"PeriodicalIF":1.5000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11130981/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Central European Journal of Immunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5114/ceji.2024.136512","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/4/19 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Eosinophilia is a feature of multiple conditions, both hematologic and non-hematologic, and may be associated with organ damage. The pathogenesis of eosinophilia can follow two distinct pathways. Primary eosinophilia is caused by a cell-intrinsic mechanism originating from clonal expansion of eosinophils through acquisition of a somatic mutation, such as FIP1L1-PDGFRA. In recent years, great progress has been made in the field of pathogenesis and molecularly targeted therapy of neoplastic eosinophilia. The diagnostic procedure should include, among other things, morphologic analysis of blood and bone marrow samples, cytogenetics and fluorescence in situ-hybridization tests to detect evidence of an acute or chronic myeloid or lymphoid disorder. Secondary eosinophilia follows a cell-extrinsic mechanism as a response to exogenous cytokines. In most clinical cases, peripheral blood eosinophilia is reactive and typically associated with non-hematological disorders such as infections, allergic conditions, connective tissue disorders, vasculitis, malignancy, or endocrinopathies. Nonetheless, the cause of most cases of hypereosinophilic syndrome remains unknown. In this article, we present a short review focused on differential diagnosis of eosinophilia and eosinophilic disorders. The diagnosis of eosinophilia is a challenge for physicians; thus this review may be useful in clinical practice.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
嗜酸性粒细胞增多症和嗜酸性粒细胞失调症的诊断和分类难题:综述。
嗜酸性粒细胞增多是血液病和非血液病等多种疾病的特征之一,可能与器官损伤有关。嗜酸性粒细胞增多症的发病机制有两种不同的途径。原发性嗜酸性粒细胞增多症是由细胞内在机制引起的,源于嗜酸性粒细胞通过获得体细胞突变(如 FIP1L1-PDGFRA)而导致的克隆性扩增。近年来,在肿瘤性嗜酸性粒细胞增多症的发病机制和分子靶向治疗领域取得了重大进展。诊断程序应包括血液和骨髓样本的形态学分析、细胞遗传学和荧光原位杂交试验等,以检测急性或慢性髓系或淋巴系统疾病的证据。继发性嗜酸性粒细胞增多是对外源性细胞因子的反应,是一种细胞外在机制。在大多数临床病例中,外周血嗜酸性粒细胞增多是反应性的,通常与非血液病有关,如感染、过敏性疾病、结缔组织病、血管炎、恶性肿瘤或内分泌病。然而,大多数嗜酸性粒细胞过多综合征病例的病因仍然不明。本文将对嗜酸性粒细胞增多症和嗜酸性粒细胞疾病的鉴别诊断进行简要综述。对医生来说,嗜酸性粒细胞增多症的诊断是一项挑战;因此,这篇综述可能对临床实践有所帮助。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
3.00
自引率
0.00%
发文量
17
审稿时长
6-12 weeks
期刊介绍: Central European Journal of Immunology is a English-language quarterly aimed mainly at immunologists.
期刊最新文献
Notch signaling pathway-based classification of bladder cancer in relation to tumor immune infiltration Interleukin-1 receptor-associated kinase 2 promotes inflammatory reactions by activating the nuclear factor kappa-B signaling pathway in diabetic nephropathy Influence of blood sample storage and different types of anticoagulants on results of NK cytotoxicity tests COVID-19 vaccination in healthcare workers: Long-term benefits and protection Efficacy of IL-23 inhibitors and IL-12/23 inhibitors in the induction treatment of Crohn’s disease: A meta-analysis based on randomized controlled trials
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1